Document is current
Any future updates will be listed below
-
Authors
Krebs, Simone https://orcid.org/0000-0002-9909-4531
Baird, Lisa
Pirovano, Giacomo
Yamaguchi, Aiko
Coll, Ryan P.
Lee, Jason T.
Carroll, Laurence S.
Pomper, Martin G.
Manning, H. Charles
-
Funding
Funding for this research was provided by:
NIH (R37 CA262557, R21 CA294042)
Cancer Prevention and Research Institute of Texas (RP200046)
- License Information
-
More Information
Article History
Received: 2 August 2025
Revised: 2 August 2025
Accepted: 8 September 2025
First Online: 19 September 2025
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: SK has a patent on THOR cell (tumor homing radio-emitting cell)—“THOR” C825 expressing immune cells and diagnostic uses thereof, and a patent on Anti-IL13ralpha2 antibody compositions and uses thereof issued. GP is an employee and shareholder of Evergreen Theragnostics, Inc. MP is a coinventor on a U.S. patent covering PYLARIFY® and as such is entitled to a portion of licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. The authors report no other relevant conflicts.
